Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

doi:10.4251/wjgo.v16.i8.3521

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-3)

Sum=0

Aug 15, 2024 (publication date) through Aug 7, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3521-3528
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3521

Table 1 Baseline characteristics

Characteristics
Number of patients	124
Age (yr)	56 (29-83)
Sex, n (%)
Male	69 (56)
Female	55 (44)
Tumor sidedness, n (%)
Right	32 (26)
Left	92 (74)
RAS mutational status, n (%)
Wild type	64 (52)
Mutation	60 (48)
TMB status, n (%)
TMB-low	99 (80)
TMB-high	25 (20)
Status of MSI (by IHC), n (%)
MSS	120 (97)
MSI-high	4 (3)
PD-L1 status, n (%)
PD-L1 CPS ≥ 1	105 (85)
PD-L1 CPS ≥ 5	64 (52)
PD-L1 CPS ≥ 10	32 (26)
Chemotherapy backbone with bevacizumab as first-line treatment, n (%)
FOLFOX	96 (77)
FOLFIRI	28 (23)

RAS: Rat sarcoma; TMB: Tumor mutational burden; MSI: Microsatellite instability; IHC: Immunohistochemistry; MSS: Microsatellite stability; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score.

Table 2 Tumor response to first-line chemotherapy containing bevacizumab, n (%)

Response
CR	3 (3)
PR	51 (41)
SD	56 (45)
PD	9 (7)
Unknown	5 (4)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Disease progression.

Table 3 Progression-free survival and overall survival according to programmed cell death ligand 1 expression level

	Patients, n (%)	Progression-free survival (months)	P value²	Overall survival (months)	P value²
PD-L1 CPS < 1¹	19 (15)	22.4 (15.63-27.30)	P = 0.152	33.7 (NA)	P = 0.863
PD-L1 CPS ≥ 1	105 (85)	13.2 (14.91-20.10)		35.9 (16.84-55.02)
PD-L1 CPS < 5	60 (48)	16.7 (15.80-22.60)	P = 0.409	49.6 (20.89-78.97)	P = 0.746
PD-L1 CPS ≥ 5	64 (52)	12.1 (13.81-20.47)		30.1 (24.96-34.24)
PD-L1 CPS < 10	92 (74)	13.7 (15.35-20.77)	P = 0.529	49.9 (32.10-67.77)	P = 0.529
PD-L1 CPS ≥ 10	32 (26)	13.5 (13.52-23.45)		29.6 (21.65-37.49)

¹Programmed cell death ligand 1 expression was evaluated with various immunohistochemistry platforms using 22C3 antibody and determined with combined positive score.

²Kaplan-Meier methods and Cox-proportional hazards models were used for calculating P values and hazard ratios.

PD-L1: Programmed cell death ligand 1; CPS: Combined positive score.

Citation: Kang SW, Lim SH, Kim MJ, Lee J, Park YS, Lim HY, Kang WK, Kim ST. Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1. World J Gastrointest Oncol 2024; 16(8): 3521-3528
URL: https://www.wjgnet.com/1948-5204/full/v16/i8/3521.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i8.3521